Harmonized Lab Data Analysis Helps Pharma Company Fight Rare Disease
See how timelier data-driven insights enabled faster identification and targeting of potential rare disease patients and treating HCPs.
New industry evidence demands RWD disruption in pharma
Reuters Events, in partnership with Prognos Health, surveyed 215 brand, marketing, commercial strategy, medical affairs, and data science professionals in the pharmaceutical industry to understand current challenges and opportunities with real-world data (RWD) for therapy commercialization.
5 Step Guide to Better Underwriting Risk Prediction
Leverage the clinical and diagnostic value of lab data to predict the future cost of healthcare more accurately than manual rate and prescription claims data alone with the PrognosⓇ Underwriting Risk Prediction tool.
A Straighter Path to Underwriting
A straighter path to underwriting requires data to accurately predict risk, the visibility to identify high-cost prospects, and insights on the populations you want to insure.
Prognos Factor Explained
Analyzing de-identified patient data is essential to optimize commercial brand strategy. But current methods of obtaining this data can be challenging. See how you can accelerate your path to clinical truth with interoperable patient data and analytics software.